CN103796648B - 用γ-醛酮清除剂治疗炎症和高血压的方法 - Google Patents

用γ-醛酮清除剂治疗炎症和高血压的方法 Download PDF

Info

Publication number
CN103796648B
CN103796648B CN201280044440.6A CN201280044440A CN103796648B CN 103796648 B CN103796648 B CN 103796648B CN 201280044440 A CN201280044440 A CN 201280044440A CN 103796648 B CN103796648 B CN 103796648B
Authority
CN
China
Prior art keywords
inflammatory
inflammation
compounds
acid
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280044440.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103796648A (zh
Inventor
L·杰克逊·罗伯茨
维卡塔拉曼·阿马尔纳特
大卫·G·哈里森
安妮特·克拉伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to CN201910951171.5A priority Critical patent/CN111494352A/zh
Publication of CN103796648A publication Critical patent/CN103796648A/zh
Application granted granted Critical
Publication of CN103796648B publication Critical patent/CN103796648B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280044440.6A 2011-07-12 2012-07-12 用γ-醛酮清除剂治疗炎症和高血压的方法 Active CN103796648B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910951171.5A CN111494352A (zh) 2011-07-12 2012-07-12 用γ-醛酮清除剂治疗炎症和高血压的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
US61/506,848 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910951171.5A Division CN111494352A (zh) 2011-07-12 2012-07-12 用γ-醛酮清除剂治疗炎症和高血压的方法

Publications (2)

Publication Number Publication Date
CN103796648A CN103796648A (zh) 2014-05-14
CN103796648B true CN103796648B (zh) 2019-10-25

Family

ID=47506934

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280044440.6A Active CN103796648B (zh) 2011-07-12 2012-07-12 用γ-醛酮清除剂治疗炎症和高血压的方法
CN201910951171.5A Pending CN111494352A (zh) 2011-07-12 2012-07-12 用γ-醛酮清除剂治疗炎症和高血压的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910951171.5A Pending CN111494352A (zh) 2011-07-12 2012-07-12 用γ-醛酮清除剂治疗炎症和高血压的方法

Country Status (13)

Country Link
US (4) US10975033B2 (https=)
EP (1) EP2731597B1 (https=)
JP (1) JP6280033B2 (https=)
KR (2) KR20140050661A (https=)
CN (2) CN103796648B (https=)
AU (1) AU2012281061B2 (https=)
BR (1) BR112014000810A8 (https=)
CA (1) CA2844150C (https=)
ES (1) ES2970814T3 (https=)
HU (1) HUE065757T2 (https=)
MX (1) MX383365B (https=)
PL (1) PL2731597T3 (https=)
WO (1) WO2013010034A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US11400103B2 (en) 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US10166248B1 (en) 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
EP3481798A4 (en) * 2016-07-06 2020-03-11 Vanderbilt University USE OF REACTIVE GAMMA KETOALDEHYDE CATCHERS TO EXTEND THE LIFE AND HEALTH OF CELLS
CA3030149A1 (en) * 2016-07-07 2018-01-11 Vanderbilt University Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
EP3510014B1 (en) 2016-09-06 2026-04-29 Metabolic Technologies, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN110177463B (zh) * 2016-11-15 2022-03-08 范德比尔特大学 2-羟基苄胺在治疗和预防肺动脉高压中的应用
WO2018201074A1 (en) 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
BR112020004372A2 (pt) * 2017-09-05 2020-09-08 Mti Biotech, Inc. método para tratar, prevenir ou melhorar fibrose hepática em um indivíduo.
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
MX2022009256A (es) * 2020-01-27 2022-10-07 Univ Vanderbilt Depuradores de isocetal/isolevuglandina dirigidos a la mitocondria y usos de los mismos.
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036109A2 (en) * 2000-11-02 2002-05-10 University Of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) * 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
CA2219944A1 (en) 1995-05-19 1996-11-21 Miho Kobayashi 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) * 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
ES2600919T3 (es) * 2007-10-05 2017-02-13 Index Pharmaceuticals Ab Oligonucleótidos para el tratamiento o alivio de edema
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036109A2 (en) * 2000-11-02 2002-05-10 University Of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sean S. Davies 等.Pyridoxamine Analogues Scavenge Lipid-Derived ç-Ketoaldehydes and Protectagainst H2O2-Mediated Cytotoxicity.《Biochemistry》.2006,第45卷第15756-15767页. *

Also Published As

Publication number Publication date
JP6280033B2 (ja) 2018-02-14
EP2731597C0 (en) 2023-12-20
KR20190069607A (ko) 2019-06-19
PL2731597T3 (pl) 2024-04-29
MX2014000515A (es) 2014-03-27
HUE065757T2 (hu) 2024-06-28
KR102050700B1 (ko) 2019-11-29
AU2012281061B2 (en) 2017-08-03
EP2731597A4 (en) 2015-04-08
AU2012281061A1 (en) 2014-02-20
CN111494352A (zh) 2020-08-07
US20250034093A1 (en) 2025-01-30
WO2013010034A3 (en) 2013-03-28
BR112014000810A2 (pt) 2017-06-13
US20140256774A1 (en) 2014-09-11
KR20140050661A (ko) 2014-04-29
CA2844150A1 (en) 2013-01-17
US20210261508A1 (en) 2021-08-26
US20250214939A1 (en) 2025-07-03
EP2731597B1 (en) 2023-12-20
BR112014000810A8 (pt) 2022-11-29
CN103796648A (zh) 2014-05-14
US10975033B2 (en) 2021-04-13
WO2013010034A2 (en) 2013-01-17
EP2731597A2 (en) 2014-05-21
JP2014524918A (ja) 2014-09-25
MX383365B (es) 2025-03-13
CA2844150C (en) 2019-09-03
ES2970814T3 (es) 2024-05-30

Similar Documents

Publication Publication Date Title
CN103796648B (zh) 用γ-醛酮清除剂治疗炎症和高血压的方法
JP6929425B2 (ja) ピペリジニルインドール誘導体の新規な使用
JP5747414B2 (ja) α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
JP6499077B2 (ja) アルツハイマー病と関連疾患の治療のための併用療法
JP2019523758A (ja) 神経変性障害を治療するための腸内微生物叢の制御
Lin et al. Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer’s Disease
Ji et al. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau. P301S mouse model of Alzheimer’s disease and frontotemporal dementia
US12060379B2 (en) Plasmalogen derivatives
Verma et al. Chronic anatabine treatment reduces Alzheimer’s disease (AD)-like pathology and improves socio-behavioral deficits in a transgenic mouse model of AD
JP2022046654A (ja) γ-ケトアルデヒドスカベンジャーによるアテローム性動脈硬化症の治療方法
US8541435B2 (en) Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
JP2017119722A (ja) タウ凝集阻害剤
KR20180090778A (ko) App-선택적 bace 억제를 위한 조성물 및 그의 용도
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
HK40023703A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
US20050113443A1 (en) Modulation of airway inflammation in patients with cystic fibrosis and related diseases
CN113272308A (zh) 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
JP6353159B2 (ja) Tlr非依存性低分子アジュバント
TW201038265A (en) Agent for treatment of cognitive impairment
HK1191859A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
HK1191859B (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
US12139505B2 (en) Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
RU2712229C2 (ru) Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
KR20150013122A (ko) 염증을 치료하고 면역 반응을 조절하기 위한 화합물 및 이의 용도
Roberts II Opening lecture

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: ROBERTS L. JACKSON

Inventor after: AMARNATH VENKATARAMAN

Inventor after: HARRISON DAVID G.

Inventor after: L Jackson Roberts Amaernate Venkataraman, David G Harrison Annette clapper

Inventor before: ROBERTS L. JACKSON

Inventor before: AMARNATH VENKATARAMAN

Inventor before: HARRISON DAVID G.

GR01 Patent grant
GR01 Patent grant